WANY
GDTC icon

Wealthspire Advisors (New York)’s CytoMed Therapeutics GDTC Stock Holding History

Wealthspire Advisors (New York)’s Portfolio GDTC Stock Details GDTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,835
Closed -$9.62K – 1753
2025
Q3 		$9.62K Buy
+4,835
New +$9.48K ﹤0.01% 2039

Other funds holding GDTC

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wealthspire Advisors (New York)'s GDTC Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of CytoMed Therapeutics (GDTC) in Q4 2025, closing a stake of 4,835 shares — an estimated $9.62K sold.

Wealthspire Advisors (New York) first reported a position in GDTC in Q3 2025 and held it in 1 quarter. The position peaked at $9.62K in Q3 2025. 5 funds tracked by Wall St. Rank hold GDTC as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining CytoMed Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 4,835 CytoMed Therapeutics shares in Q4 2025, an estimated $9.62K.
  • Wealthspire Advisors (New York) first reported a position in CytoMed Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s CytoMed Therapeutics position peaked at $9.62K in Q3 2025.
  • 5 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.